Product Description
Entecavir is used to treat chronic (long-term) hepatitis B infection (swelling of the liver caused by a virus) in adults and children 2 years of age and older who have liver damage. Entecavir is in a class of medications called nucleoside analogs. It works by decreasing the amount of hepatitis B virus (HBV) in the body. Entecavir does not cure HBV and may not prevent complications of chronic hepatitis B such as cirrhosis of the liver or liver cancer. Entecavir does not prevent the spread of HBV to other people (Sourced from: https://medlineplus.gov/druginfo/meds/a605028.html)
Mechanisms of Action: Nucleoside Polymerase Inhibitor,HBV-NART Inhibitor,NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Hepatitis B, Chronic
Phase 2: Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| APG1387BC201 | P2 |
Recruiting |
Hepatitis A|Hepatitis B, Chronic |
2022-10-31 |
24% |
| APG1387BC201 | P2 |
Recruiting |
Hepatitis A|Hepatitis B, Chronic |
2022-10-31 |
24% |
| CTR20210513 | P3 |
Recruiting |
Hepatitis B, Chronic |
None |
|
| CTR20182060 | P2 |
Recruiting |
Hepatitis B, Chronic |
None |
|
| CTR20221976 | P2 |
Recruiting |
Hepatitis B, Chronic |
None |